It's disturbing that Veneto likely has yearly revenues of 20 million instead of 60, but the only thing to do at this point is realize that there are many other pieces to Generex than Veneto, and this current revenue shortfall isn't the end of the world.
I don't know how to evaluate the old deal vs the new deal, so will just trust Joe that is is fair and square. And why would he negotiate a bad deal anyway? Seems unlikely.
(2)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links